Cargando…
Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers
STRO-002 is a novel homogeneous folate receptor alpha (FolRα) targeting antibody–drug conjugate (ADC) currently being investigated in the clinic as a treatment for ovarian and endometrial cancers. Here, we describe the discovery, optimization, and antitumor properties of STRO-002. STRO-002 was gener...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890132/ https://www.ncbi.nlm.nih.gov/pubmed/36459691 http://dx.doi.org/10.1158/1535-7163.MCT-22-0322 |
_version_ | 1784880888082857984 |
---|---|
author | Li, Xiaofan Zhou, Sihong Abrahams, Cristina L. Krimm, Stellanie Smith, Jennifer Bajjuri, Krishna Stephenson, Heather T. Henningsen, Robert Hanson, Jeffrey Heibeck, Tyler H. Calarese, Daniel Tran, Cuong Yin, Gang Stafford, Ryan L. Yam, Alice Y. Kline, Toni De Almeida, Venita I. Sato, Aaron K. Lupher, Mark Bedard, Kristin Hallam, Trevor J. |
author_facet | Li, Xiaofan Zhou, Sihong Abrahams, Cristina L. Krimm, Stellanie Smith, Jennifer Bajjuri, Krishna Stephenson, Heather T. Henningsen, Robert Hanson, Jeffrey Heibeck, Tyler H. Calarese, Daniel Tran, Cuong Yin, Gang Stafford, Ryan L. Yam, Alice Y. Kline, Toni De Almeida, Venita I. Sato, Aaron K. Lupher, Mark Bedard, Kristin Hallam, Trevor J. |
author_sort | Li, Xiaofan |
collection | PubMed |
description | STRO-002 is a novel homogeneous folate receptor alpha (FolRα) targeting antibody–drug conjugate (ADC) currently being investigated in the clinic as a treatment for ovarian and endometrial cancers. Here, we describe the discovery, optimization, and antitumor properties of STRO-002. STRO-002 was generated by conjugation of a novel cleavable 3-aminophenyl hemiasterlin linker-warhead (SC239) to the nonnatural amino acid para-azidomethyl-L-phenylalanine incorporated at specific positions within a high affinity anti-FolRα antibody using Sutro's XpressCF+, which resulted in a homogeneous ADC with a drug–antibody ratio (DAR) of 4. STRO-002 binds to FolRα with high affinity, internalizes rapidly into target positive cells, and releases the tubulin-targeting cytotoxin 3-aminophenyl hemiasterlin (SC209). SC209 has reduced potential for drug efflux via P-glycoprotein 1 drug pump compared with other tubulin-targeting payloads. While STRO-002 lacks nonspecific cytotoxicity toward FolRα-negative cell lines, bystander killing of target negative cells was observed when cocultured with target positive cells. STRO-002 is stable in circulation with no change in DAR for up to 21 days and has a half-life of 6.4 days in mice. A single dose of STRO-002 induced significant tumor growth inhibition in FolRα-expressing xenograft models and patient-derived xenograft models. In addition, combination treatment with carboplatin or Avastin further increased STRO-002 efficacy in xenograft models. The potent and specific preclinical efficacy of STRO-002 supports clinical development of STRO-002 for treating patients with FolRα-expressing cancers, including ovarian, endometrial, and non–small cell lung cancer. Phase I dose escalation for STRO-002 is in progress in ovarian cancer and endometrial cancer patients (NCT03748186 and NCT05200364). |
format | Online Article Text |
id | pubmed-9890132 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-98901322023-02-03 Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers Li, Xiaofan Zhou, Sihong Abrahams, Cristina L. Krimm, Stellanie Smith, Jennifer Bajjuri, Krishna Stephenson, Heather T. Henningsen, Robert Hanson, Jeffrey Heibeck, Tyler H. Calarese, Daniel Tran, Cuong Yin, Gang Stafford, Ryan L. Yam, Alice Y. Kline, Toni De Almeida, Venita I. Sato, Aaron K. Lupher, Mark Bedard, Kristin Hallam, Trevor J. Mol Cancer Ther MCT First Disclosures STRO-002 is a novel homogeneous folate receptor alpha (FolRα) targeting antibody–drug conjugate (ADC) currently being investigated in the clinic as a treatment for ovarian and endometrial cancers. Here, we describe the discovery, optimization, and antitumor properties of STRO-002. STRO-002 was generated by conjugation of a novel cleavable 3-aminophenyl hemiasterlin linker-warhead (SC239) to the nonnatural amino acid para-azidomethyl-L-phenylalanine incorporated at specific positions within a high affinity anti-FolRα antibody using Sutro's XpressCF+, which resulted in a homogeneous ADC with a drug–antibody ratio (DAR) of 4. STRO-002 binds to FolRα with high affinity, internalizes rapidly into target positive cells, and releases the tubulin-targeting cytotoxin 3-aminophenyl hemiasterlin (SC209). SC209 has reduced potential for drug efflux via P-glycoprotein 1 drug pump compared with other tubulin-targeting payloads. While STRO-002 lacks nonspecific cytotoxicity toward FolRα-negative cell lines, bystander killing of target negative cells was observed when cocultured with target positive cells. STRO-002 is stable in circulation with no change in DAR for up to 21 days and has a half-life of 6.4 days in mice. A single dose of STRO-002 induced significant tumor growth inhibition in FolRα-expressing xenograft models and patient-derived xenograft models. In addition, combination treatment with carboplatin or Avastin further increased STRO-002 efficacy in xenograft models. The potent and specific preclinical efficacy of STRO-002 supports clinical development of STRO-002 for treating patients with FolRα-expressing cancers, including ovarian, endometrial, and non–small cell lung cancer. Phase I dose escalation for STRO-002 is in progress in ovarian cancer and endometrial cancer patients (NCT03748186 and NCT05200364). American Association for Cancer Research 2023-02-01 2022-11-30 /pmc/articles/PMC9890132/ /pubmed/36459691 http://dx.doi.org/10.1158/1535-7163.MCT-22-0322 Text en ©2022 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. |
spellingShingle | MCT First Disclosures Li, Xiaofan Zhou, Sihong Abrahams, Cristina L. Krimm, Stellanie Smith, Jennifer Bajjuri, Krishna Stephenson, Heather T. Henningsen, Robert Hanson, Jeffrey Heibeck, Tyler H. Calarese, Daniel Tran, Cuong Yin, Gang Stafford, Ryan L. Yam, Alice Y. Kline, Toni De Almeida, Venita I. Sato, Aaron K. Lupher, Mark Bedard, Kristin Hallam, Trevor J. Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers |
title | Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers |
title_full | Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers |
title_fullStr | Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers |
title_full_unstemmed | Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers |
title_short | Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers |
title_sort | discovery of stro-002, a novel homogeneous adc targeting folate receptor alpha, for the treatment of ovarian and endometrial cancers |
topic | MCT First Disclosures |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890132/ https://www.ncbi.nlm.nih.gov/pubmed/36459691 http://dx.doi.org/10.1158/1535-7163.MCT-22-0322 |
work_keys_str_mv | AT lixiaofan discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT zhousihong discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT abrahamscristinal discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT krimmstellanie discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT smithjennifer discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT bajjurikrishna discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT stephensonheathert discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT henningsenrobert discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT hansonjeffrey discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT heibecktylerh discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT calaresedaniel discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT trancuong discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT yingang discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT staffordryanl discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT yamalicey discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT klinetoni discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT dealmeidavenitai discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT satoaaronk discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT luphermark discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT bedardkristin discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers AT hallamtrevorj discoveryofstro002anovelhomogeneousadctargetingfolatereceptoralphaforthetreatmentofovarianandendometrialcancers |